Hubei Mengyang Pharmaceutical

About Hubei Mengyang Pharmaceutical

Hubei Mengyang Pharmaceutical, established in February 2009, is a high-tech pharmaceutical enterprise based in Jingmen City, Hubei Province. The company integrates the research, development, production, and marketing of natural drugs and health foods. Its core mission is to improve the quality of life for cancer patients, with a focus on addressing unmet clinical needs in cancer treatment-related diseases.

The company's product portfolio is rooted in traditional Chinese medicine, aiming to develop new drugs from classic prescriptions and effective ingredients from natural medicines. A key product, "Shengbai Oral Liquid," was developed by the renowned traditional Chinese medicine doctor Professor Shao Mengyang to treat leukopenia caused by tumor radiotherapy and chemotherapy. Other significant products include the "Polyporus Capsule," for liver protection and immune enhancement, developed by a team led by Professor Zhang Ronglie, and two health foods, "Huangqi Beishachan Granules" and "Rhodiola Astragalus Granules," developed by Professor Lin Hongsheng for the physical recuperation of cancer patients in rehabilitation.

Mengyang Pharmaceutical also operates a wholly-owned subsidiary in Shanghai, which serves as a base for innovative drug research, development, and production of high-end and biological preparations. The research and development pipeline includes several new small-molecule drugs. One such drug, DH001, designed to reduce cardiotoxicity from adriamycin treatment, has entered phase II clinical studies. Other drugs in development, like MY0063 for chemotherapy-induced thrombocytopenia and MY00 for acute radiation sickness, are still in earlier stages. The company's business model encompasses a strong marketing network, academic collaboration, and multiple cooperation models to bring its products to market.